145 related articles for article (PubMed ID: 29478116)
1. The Australian Managed Entry Scheme: Are We Getting it Right?
Tuffaha HW; Scuffham PA
Pharmacoeconomics; 2018 May; 36(5):555-565. PubMed ID: 29478116
[TBL] [Abstract][Full Text] [Related]
2. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Wonder M; Dunlop S
Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
[TBL] [Abstract][Full Text] [Related]
4. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
5. Improving Access to High-Cost Technologies in the Asia Region.
Mundy L; Trowman R; Kearney B
Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
[TBL] [Abstract][Full Text] [Related]
6. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
Wonder M; Backhouse ME; Sullivan SD
Value Health; 2012 May; 15(3):586-90. PubMed ID: 22583471
[TBL] [Abstract][Full Text] [Related]
7. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
Turkstra E; Bettington E; Donohue ML; Mervin MC
Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
[TBL] [Abstract][Full Text] [Related]
8. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
9. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Kim H; Byrnes J; Goodall S;
Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
[TBL] [Abstract][Full Text] [Related]
10. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Lopert R
Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
[TBL] [Abstract][Full Text] [Related]
12. Tailoring access to high cost, genetically targeted drugs.
Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
[TBL] [Abstract][Full Text] [Related]
13. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
14. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
15. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
[TBL] [Abstract][Full Text] [Related]
16. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Wonder MJ; Neville AM; Parsons R
Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
[TBL] [Abstract][Full Text] [Related]
17. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
18. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.
Bailey C; Dalziel K; Cronin P; Devlin N; Viney R;
Pharmacoeconomics; 2022 Feb; 40(2):157-182. PubMed ID: 34738210
[TBL] [Abstract][Full Text] [Related]
19. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
Robertson J; Walkom EJ; Bevan MD; Newby DA
BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
[TBL] [Abstract][Full Text] [Related]
20. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
